NHS Greater Glasgow and Clyde intends to purchase Ru-106 Eye Applicators from Eckert & Ziegler for specialist ocular brachytherapy treatments delivered within NHS Scotland. The purchase includes the supply of radioactive Ru-106 ophthalmic applicators and associated technical support services as required by the clinical service.

Ru-106 eye applicators are ophthalmic brachytherapy plaques used primarily for treating uveal melanoma, retinoblastoma, and other ocular tumors. They consist of a thin film of Ru-106 beta-emitting isotope, encapsulated in pure silver sheets, with a total thickness of only 1 mm, making them easy to handle and position on the eye surface. The beta radiation has a limited range, allowing high doses to tumors up to 5 mm in thickness while sparing sensitive structures like the optic disc and fovea.